CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Pybus, Brandon S ^a   Sousa, Jason C ^a   Jin, Xiannu ^a   Ferguson, James A ^b   Christian, Robert E ^b   Barnhart, Rebecca ^a   Vuong, Chau ^a   Sciotti, Richard J ^a   Reichard, Gregory A ^a   Kozar, Michael P ^a   Walker, Larry A ^c   Ohrt, Colin ^a   Melendez, Victor ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b MDS SCIEX   (Canada)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 AMINOQUINOLINE DERIVATIVE; ALDEHYDE; AMINE OXIDASE (FLAVIN CONTAINING); CARBOXYL GROUP; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DRUG METABOLITE; PRIMAQUINE;

ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG HYDROXYLATION; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PHENOTYPE; TOXICITY;

AMINOQUINOLINES; ANTIMALARIALS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MASS SPECTROMETRY; METABOLIC NETWORKS AND PATHWAYS; PRIMAQUINE; RECOMBINANT PROTEINS;

EID: 84864473749     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-259     Document Type: Article

References (19)

1. WHO, World Malaria Report 2011 World Health Organization, Geneva 2011
2. Mapping the global extent of malaria in 2005. Guerra CA, Snow RW, Hay SI, Trends Parasitol 2006 22 353 358 10.1016/j.pt.2006.06.006 16798089
3. Vivax malaria: neglected and not benign. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM, AmJTrop Med Hyg 2007 77 79 87
4. Primaquine-induced hemolytic anemia: formation and hemotoxicity of the arylhydroxylamine metabolite 6-methoxy-8-hydroxylaminoquinoline. Bolchoz LJ, Budinsky RA, McMillan DC, Jollow DJ, J Pharmacol Exp Ther 2001 297 509 515 11303037
5. Hydroxylated metabolites of the antimalarial drug primaquine. Vasquez-Vivar J, Augusto O, JBC 1992 267 6848 6854
6. Drug-induced hemolytic anemia. Beutler E, Pharmacol Rev 1969 21 73 103 4887725
7. Primaquine induced hemolytic anemia: susceptibility of normal versus glutathione-depleted rat erythrocytes to 5-hydroxyprimaquine. Bowman ZS, Oatis JE, Whelan JL, Jollow DJ, McMillan DC, J Pharmacol Exp Ther 2004 309 79 85 10.1124/jpet.103.062984 14724225
8. Structure-activity relationships of putative primaquine metabolites causing methemoglobin formation in canine hemolysates. Link CM, Theoharides AD, Anders JC, Chung H, Canfield CJ, Toxicol Appl Pharmacol 1985 81 192 202 10.1016/0041-008X(85)90155-3 4060148
9. Cytochrome P450-dependent toxic effects of primaquine on human erythrocytes. Ganesan S, Tekwani BL, Sahu R, Tripathi LM, Walker LA, Tox App Pharm 2009 241 14 22 10.1016/j.taap.2009.07.012
10. Metabolism of primaquine by liver homogenate fractions: Evidence for monoamine oxidase and cytochrome P450 involvement in the oxidative deamination of primaquine to carboxyprimaquine. Constantino L, Paixao P, Moreira R, Portela MJ, Do Rosario VE, Iley J, Exp Toxic Pathol 1999 51 299 303 10.1016/S0940- 2993(99)80010-4
11. The use of heterologously expressed drug metabolizing enzymes-state of the art and prospects for the future. Crespi CL, Miller VP, Pharmacol Ther 1999 84 121 131 10.1016/S0163-7258(99)00028-5 10596902
12. Antimalarial activity and inhibition of monoamine oxidases A and B by exo-erythrocytic antimalarials. Brossi A, Millet P, Landau I, Bembenek ME, Abell CW, FEBS 1987 214 291 294 10.1016/0014-5793(87)80072-8
13. Pharmacokinetic interactions of antimalarial agents. Gia PT, deVries PJ, Clin Pharmacokinet 2001 40 343 373 10.2165/00003088-200140050-00003 11432537
14. In vitro metabolism of choroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing n-desethylchloroquine formation. Projean D, Baune B, Farinotti R, Flinois J, Beaune P, Taburet A, Ducharme J, Drug Metab Dispos 2003 31 748 754 10.1124/dmd.31.6.748 12756207
15. High-performance liquid chromatographic analysis of the metabolism of primaquine and the identification of a new mammalian metabolite. Baker JK, McChesney JD, Hufford CD, Clark AM, J Chromatogr 1982 230 69 77 10.1016/S0378-4347(00)81431-0 7107769
16. Side-chain hydroxylation in the metabolism of 8-aminoquinoline antiparasitic agents. Idowu OR, Peggins JO, Brewer TG, Drug Metab Dispos 1995 23 18 27 7720521
17. Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme ML, Breckenridge AM, Br J Clin Pharmacol 1985 19 745 750 10.1111/j.1365-2125.1985.tb02709.x 4027117
18. Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. Mihaly GW, Ward SA, Edwards G, Orme ML, Breckenridge AM, Br J Clin Pharmacol 1984 17 441 446 10.1111/j.1365-2125.1984.tb02369.x 6721990
19. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): population distribution of CYP2D6 activity. Neafsey P, Ginsberg G, Hattis D, Sonawane B, J Tox Env Health B 2009 12 334 361 10.1080/10937400903158342